ABG
MLTX icon

Ally Bridge Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

Ally Bridge Group’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-69,000
Closed -$495K – 25
2025
Q3 		$495K Buy
+69,000
New +$3.6M 0.3% 23

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Ally Bridge Group's MLTX Position: Q1 2024 in Review

Ally Bridge Group sold out of MoonLake Immunotherapeutics (MLTX) in Q1 2024, closing a stake of 143,479 shares — an estimated $8.66M sold.

Ally Bridge Group first reported a position in MLTX in Q1 2023 and held it in 4 quarters. The position peaked at $10.4M in Q3 2023. 114 funds tracked by Wall St. Rank hold MLTX as of Q1 2024.

  • Ally Bridge Group reported no remaining MoonLake Immunotherapeutics position as of Q1 2024 after selling out during the quarter.
  • Ally Bridge Group sold 143,479 MoonLake Immunotherapeutics shares in Q1 2024, an estimated $8.66M.
  • Ally Bridge Group first reported a position in MoonLake Immunotherapeutics in Q1 2023 and held it in 4 quarters.
  • Ally Bridge Group's MoonLake Immunotherapeutics position peaked at $10.4M in Q3 2023.
  • 114 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2024.

Based on Ally Bridge Group's 13F filing for Q1 2024, filed 15 May 2024.